Peptides and soft tissue healing: what research shows

GH-releasing peptide-6 overcomes refractoriness of somatotropes to GHRH after feeding, C D McMahon, Journal of Endocrinology (2001) 170, 235–241 After a meal, somatotropes are temporarily refractory to growth hormone-releasing hormone (GHRH), the principal hormone that stimulates secretion of growth hormone (GH). Refractoriness is particularly evident when free access to feed is restricted to a 2-h period each day. GH-releasing peptide-6 (GHRP-6), a synthetic peptide, also stimulates secretion of GH from somatotropes. Because GHRH and GHRP-6 act via different receptors, we hypothesized that GHRP-6 would increase GHRH-induced secretion of GH after feeding. Initially, we determined that intravenous injection of GHRP-6 at 1, 3 and 10 ug/kg body weight (BW) stimulated secretion of GH in a dose-dependent manner. Next, we determined that GHRP-6- and GHRH-induced secretion of GH was lower 1 h after feeding (22.5ng/ml and 20 ng/ml respectively) than 1 h before feeding (53.5ng/ml and 64.5 ng/ml respectively). However, a combination of GHRP-6 at 3 ug/kg BW and GHRH at .2 ug/kg BW synergistically induced an equal and massive release of GH before and after feeding that was fivefold greater than the GHRH-induced release of GH after feeding. Furthermore, the combination of GHRP-6 and GHRH synergistically increased the release of GH from somatotropes cultured in vitro. However, it was not clear if GHRP-6 acted only on somatotropes or also acted at the hypothalamus. Therefore, we wanted to determine if GHRP-6 stimulated secretion of GHRH or inhibited secretion of somatostatin, or both. GHRP-6 stimulated secretion of GHRH from bovine hypothalamic slices but did not alter secretion of somatostatin. We conclude that GHRP-6 acts at the hypothalamus to stimulate secretion of GHRH, and at somatotropes to restore and enhance the responsiveness of somatotropes to GHRH. “Reduced secretion of GH from somatotropes after feeding is not limited to that induced by GHRH because a 2-adrenergic-induced secretion of GH is also reduced after feeding (Gaynor et al. 1993). How and why somatotropes become refractory to GHRH after feeding is not known. However, given that the combination of GHRH with GHRP-6 induced a rapid and massive release of GH before and after feeding, it seems likely that releasable pools of GH are not reduced and that receptors to GHRH and GHRP-6 are not down-regulated. Rather, it is likely that there is a change in receptor signalling after feeding that is overcome by stimulating GHRH and GHRP-6 receptors together while remaining refractory to either peptide alone.” WarningTHE GOODS OFFERED BY THE SELLER IS INTENDED FOR SCIENTIFIC AND DEVELOPMENT PURPOSES ONLY. The goods offered by the Seller include chemical substances that shall not be used as a drug, medicine, active substance, medical aid, cosmetic product, a substance for production of a cosmetic product neither for human consumption that is any food or food supplement or otherwise similarly used on humans or animals. References / Links McMahon, C. D., Chapin, L. T., Radcliff, R. P., Lookingland, K. J., & Tucker, H. A. (2001). GH-releasing peptide-6 overcomes refractoriness of somatotropes to GHRH after feeding. Journal of Endocrinology, 170(1), 235–241. DOI: 10.1677/joe.0.1700235 PubMed PubMed entry with abstract: “GH-releasing peptide-6 overcomes refractoriness of somatotropes to GHRH after feeding” — shows details, authors, doses etc. PubMed ResearchGate article page: same study summary + some related figures/discussion. ResearchGate

The assumption that drives most poorly timed protocols is that CoQ10 and peptides 'work together' simply by being present in the body at the same time. That's biochemically illiterate. Mitochondrial peptides don't enhance CoQ10 absorption. They increase the demand for CoQ10 by upregulating the rate at which electrons enter the transport chain. If CoQ10 isn't already embedded in the inner mitochondrial membrane when that upregulation begins, the increased electron flow has no shuttle. The absorption curve mismatch is the core issue. Oral CoQ10. Even in ubiquinol form. Requires 2–4 hours to reach peak intracellular concentration in mitochondria. It's absorbed in the small intestine, packaged into chylomicrons, transported through lymphatic circulation, taken up by tissues, and finally imported into mitochondrial membranes via specific carrier proteins. Peptides administered subcutaneously or intravenously bypass all of that. They reach mitochondrial targets within an hour. Most researchers dose them together because it's procedurally simpler, then attribute poor results to 'individual variation' or 'baseline mitochondrial heterogeneity' rather than recognizing they mistimed the intervention by three hours. The electron transport chain doesn't wait. If you signal it to ramp up flux without providing the electron acceptor that makes that flux productive, you get oxidative damage instead of energy production. It's not a subtle effect. Superoxide levels in mistimed protocols are 30–40% above baseline. Our team works with researchers who want reproducible mitochondrial outcomes, not variable results they can explain away post-hoc. The peptides and CoQ10 synergy timing protocol is the difference between a protocol that works consistently and one that works sometimes. There's no middle ground here. Either the timing aligns or it doesn't, and the ATP output data makes the difference unmistakable every single time. When you're ready to design a mitochondrial optimization protocol that actually synchronizes electron transport chain demand with substrate availability, explore our full peptide collection to find research-grade compounds that deliver the purity and consistency this level of precision requires. Timing doesn't matter if the peptide itself is inconsistently dosed or degraded during shipping. Both variables have to be controlled. The peptides and CoQ10 synergy timing protocol isn't an edge case for advanced researchers. It's the baseline implementation standard for anyone using mitochondrial peptides seriously. Dose CoQ10 30–45 minutes early, use ubiquinol with fat, administer peptides when CoQ10 levels peak, and measure ATP output during the 90–180 minute synergy window. That's the protocol. Everything else is guesswork dressed up as methodology.